Translating a better understanding of the microbiome, the large mass of micro-organisms that we all carry around in our gastrointestinal (GI) tract, our skin and elsewhere, into beneficial therapeutic products is proving to be a long and painstaking process. Still, it is one that may be attractive to researchers with a background in complex systems and processes.
Applying Scientific Rigor To Microbiome Therapeutics
PharmaBiome’s Second-Generation Candidates
Tomas de Wouters, one of In Vivo’s 2020 Rising Leaders, has taken on the complex challenge of the microbiome, aiming to design the next generation of microbiome therapeutic candidates targeted at host-microbial interactions.
More from Innovation
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.
• By
In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.
• By
The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.
• By
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.